BALTIMORE, MD – November 28, 2023 --- In a significant move for the biotech industry, Complete Omics Inc., a pioneering biotechnology company specializing in clinical proteomics and multi-omics diagnostics, has announced the successful closure of its Series A financing round, with a notable investment from Qiming Venture Partners. This strategic partnership marks a pivotal moment for Complete Omics, enabling the company to accelerate its research and development efforts and expand its innovative diagnostics solutions globally.
Speaking on the occasion, the CEO of Complete Omics Inc., Dr. Qing Wang, expressed profound gratitude and optimism towards the collaboration with Qiming Venture Partners. "We are immensely grateful for the trust and confidence Qiming Venture Partners has placed in us. Their investment is not just financial; it's a testament to our shared vision and mission to revolutionize the molecular diagnositics industry through innovation and excellence," the CEO stated.
Highlighting the synergy between the two entities, the CEO further elaborated, "Qiming's vision and operational strategy across the USA and China align perfectly with our development goals. This partnership is a strategic alignment of our efforts to bridge the healthcare innovation gap between these two major markets."
Qiming Venture Partners, known for its keen eye for groundbreaking ventures in the healthcare sector, sees Complete Omics Inc. as a fitting addition to its portfolio. The venture firm praised Complete Omics for its innovative approach and the potential of its technologies to address critical challenges in disease diagnostics and therapy development.
The investment from Qiming Venture Partners will empower Complete Omics Inc. to further its mission of developing next-generation clinical proteomics assays and multi-omics liquid biopsy tests. These advancements aim to fulfill the unmet needs for deep, highly accurate, but low-cost molecular diagnostics platforms. With this new funding, Complete Omics Inc. is set to embark on a new chapter of growth and innovation, promising to bring transformative changes to the healthcare and biotech industries.
About Complete Omics -
Established in 2019, Complete Omics is a pioneering biotechnology firm at the forefront of developing clinical applications within the realm of proteomics. The company has achieved remarkable innovation, securing over 20 patents globally for its cutting-edge clinical proteomics technologies. Despite the prevalent application of proteomics primarily in research sectors, there remains a significant gap in its application to critical clinical needs, such as disease screening and companion diagnostics. The demand for reliable, high-throughput, and precise quantitative protein analysis in clinical samples is increasingly becoming a pivotal concern. Complete Omics was established by a distinguished team of experts specializing in liquid biopsy and molecular diagnostics, alongside globally recognized leaders in the clinical proteomics field. The company's mission is to develop and commercialize next-generation clinical proteomics assays and multi-omics tests. These advancements aim to address the unmet need for a comprehensive, cost-effective molecular diagnostics platform. This platform is envisioned to revolutionize disease diagnostics, companion diagnostics, biomarker discovery, and provide invaluable support in drug development processes.
About Qiming Venture Partners -
Founded in 2006, Qiming Venture Partners is a leading venture capital firm with offices in the United States -- Seattle, Boston, and the San Francisco Bay Area, and China -- Shanghai, Beijing, Suzhou and Hong Kong. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since its establishment, Qiming has invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.
